SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2757Thanks. KOD is interesting to follow, but KSI-301 may not be an ideal candidate Miljenko Zuanic110/11/2019
2756FWIW: prnewswire.com prnewswire.comDewDiligence_on_SI-10/11/2019
2755Just to think a bit,....Lucentis 0.5 mg dose is not as safe as 0.3 mg (recommenMiljenko Zuanic-10/11/2019
2754I still do not believe that Eylea will lose significant (that will be hard to suMiljenko Zuanic-10/10/2019
2753I was with you until the final sentence!DewDiligence_on_SI-10/10/2019
2752REGN/MRK at ESMO2019..... One of the unknown factor in REGN future is cemiplimabMiljenko Zuanic-10/10/2019
2751Thoughts? endpts.com While I agree being a standout antibody company may not beFelix B-9/25/2019
2750BTW, carnage in sector continue. REGN is/was hit severely. For good or bad reasoMiljenko Zuanic-9/12/2019
2749RE:ADVM My exit vas bit premature, but correct, finance.yahoo.com While no rescMiljenko Zuanic-9/12/2019
2748I hope they will be able to compete as stand alone, as well in combination. REGNMiljenko Zuanic-9/11/2019
2747Ahh I see, didn't realize they were trying to go into the same indication asFelix B-9/11/2019
2746No, K-629 results will be compared with Cemiplimab, and IF equivalent (or very sMiljenko Zuanic-9/10/2019
2745Are you saying of Keynote 629 is successful than REGN can compete with them thatFelix B-9/10/2019
2744The next real test for REGN and its PD1 drug, cemiplimab, are Pemb data release Miljenko Zuanic-9/6/2019
2743It is not. siRNA still have to prove itself, and *small* data advantage for Abs Miljenko Zuanic-8/29/2019
2742Is PCSK9 over? endpts.comFelix B-8/28/2019
2741Opthea, OPT-302 Primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combMiljenko Zuanic-8/6/2019
27402Q results: investor.regeneron.com US Eylea and cemiplimab come at nice #. SomeMiljenko Zuanic-8/6/2019
2739I should know better, it is in pre-filled syringe... ema.europa.eu <1. NAME OMiljenko Zuanic-7/30/2019
2738Thanks. I guess so (crossed my mind). Anyway, REGN need fast E-pre-filled syringMiljenko Zuanic-7/30/2019
2737They may be using the average exchange rate during the quarter rather than the rDewDiligence_on_SI-7/30/2019
2736Just to clarify, based on sale in euro, 1Q=583, 2Q=604, which is 3.6% growth. REMiljenko Zuanic-7/30/2019
2735Eylea, 2Q ex-US sale (reported by Bayer) are e604 ($676, currency exchange rate Miljenko Zuanic-7/30/2019
2734IF one translate today SP action (related to Dem-Gov headline news on healthcareMiljenko Zuanic-7/29/2019
2733Lucentis 2Q US sale (Roche) are at $467M, flat over 1Q-19, and 10% growth over 2Miljenko Zuanic-7/25/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News